The Hybrid Orthomolecular Protocol is a recent, cutting-edge approach developed by scientists from the International Society for Orthomolecular Medicine (ISOM). It aims to treat cancer by targeting the mitochondrial-stem cell connection (MSCC) and cancer stem cells (CSCs), two critical aspects that contribute to cancer’s resilience and metastasis. This protocol aims to support mitochondrial health while directly targeting the energy pathways cancer cells depend on, such as glycolysis and glutaminolysis. It combines high-dose nutrients and repurposed medications known to interfere with cancer cell survival mechanisms, reduce inflammation, and enhance immune function.
At its core, the protocol relies on mechanisms that reduce cancer’s reliance on glucose and glutamine. High-dose Vitamin C, for instance, promotes oxidative stress within cancer cells, impairing their function and energy production. Zinc and Vitamin D enhance mitochondrial respiration, thus weakening the cancer cells’ survival while simultaneously slowing CSC activity. Repurposed drugs like ivermectin and fenbendazole disrupt cancer cell structures and pathways critical to cell division and nutrient uptake, essentially “starving” the cancer cells by cutting off their primary energy sources.
It’s important to note that Vitamin C needs to be injected intravenously to reach therapeutic levels effective against cancer cells. Mebendazole, while chosen here for approval status, represents the broader benzimidazole class, including fenbendazole, which disrupts cancer cell metabolism and structure.
Key Components and Directions:
1. Vitamin C: 1.5g/kg/day (intravenuos), 2-3x per week for intermediate- and high-grade cancers. Exact dosing varies based on patient tolerance.
2. Vitamin D: 50,000 IU/day for patients with a blood level ≤ 30ng/mL; 25,000 IU/day for levels 30-60ng/mL; and 5000 IU/day for levels 60-80ng/mL. It is necessary to reach a blood level of 80 ng/mL of vitamin D which is not toxic. Once this level is reached it must be maintained with a reduced daily dosage of ≈ 2000 IU/day. The vitamin D blood concentration should be measured every two weeks for high doses and monthly for lower doses.
3. Zinc: 1 mg/kg daily. The reference range for serum zinc concentration is 80 to 120 μg/dL. Once this level is reached it must be maintained with a reduced daily dosage of 5mg/day.
4. Ivermectin:
- Low-grade cancers: Dose of 0.5mg/kg, 3x per week.
- Intermediate-grade cancers: Dose of 1mg/kg, 3x per week.
- High-grade cancers: Dose from 1 mg/kg/day to 2 mg/kg/day.
5. Mebendazole:
- Low-grade cancers: Mebendazole: Dose of 200 mg/day.
- Intermediate-grade cancers: Mebendazole: Dose of 400 mg/day.
- High-grade cancers: Mebendazole dose of 1,500 mg/day or Fenbendazole 1,000 mg 3x per week.
6. 6-Diazo-5-oxo-L-norleucine (DON):
- intravenously or intramuscularly: 0.2 to 0.6 mg/kg once daily;
- or orally: 0.2 to 1.1 mg/kg once daily
DON can be prescribed as an alternative for Mebendazole, or in combination with it.
7. Ketogenic diet (low carbohydrate-high fat diet, 900 to 1500 kcal/day).
8. Moderate physical activity: 3x per week. Increased heart and respiratory rate for a period of 45 to 75 minutes with activities such as cycling, running, swimming, etc.
Dr. William Makis commended this paper for pioneering a peer-reviewed protocol focused on ivermectin, and mebendazole, noting its potential to reshape cancer treatment. More details can be found in the ISOM article.
